Abstract 2868
Background
The aims of this study were to understand the prevalence of chemotherapy (chemo) use and its associated impact on survival in patients (pts) with either bone- and soft-tissue sarcomas (STS) through a large real-world population dataset.
Methods
A population-based retrospective database was assembled to extract pts with sarcoma, as defined as ICD-9-CM codes of bone (170.x) or/and soft tissue (171.x) who have attended clinics or hospitals of the Hong Kong Hospital Authority (HA) between Jan 2004 and Mar 2018. Eligible pts with index presentation of bone or/and soft tissue sarcoma (STS) on or after Jan 2005 were analysed to allow 1-year window. Drug dispensing records of chemotherapy drugs (chemo) from the HA as categorized by the British National Formulary 8.x were extracted and correlated with all-cause and cancer specific mortality.
Results
Of 3746 pts identified, 3358 pts satisfied eligibility: bone: n = 661, STS n = 2576, both n = 121. 32.8% of pts (n = 1100) had chemo prescribed during the study period. The proportional use of chemo decreased with advancing age (<18y: 70.9%; 18-<40y: 42.2%; 40-65y: 36.1%, 65-80y: 19.7%;.>/=80y: 8.1%). Anthracyclines (AN) were the most commonly used class of chemo (19.8%), followed by alkylating drugs (17.3%), antimetabolites (11.9%) and vinca alkaloids & etoposide (8.7%). Comparing with pts who have not received chemo within the study period, the risk for death was higher in pts who have received AN either as first chemo (HR 1.51, 95%CI1.25-1.83; p < 0.001) or later lines of therapy (HR 1.55; 95%CI1.10-2.17; p = 0.002), and in pts who have had chemo but never received AN (HR 1.51; 95%CI1.27-1.80; p < 0.001). AN use resulted in significant reduction in mortality over non-AN chemo use if used within 3months of index diagnosis. This significance was not apparent in pts who started chemo >3months post diagnosis (log-rank p < 0.01 and p = 0.14 respectively). The impact of chemo on mortality reduction appeared greater in pts with bone- vs. STS.
Conclusions
This is one of the largest assembled population-based real-world sarcoma cohort. Chemo use and choice of chemo has implications on survival. The positive effect on survival was especially prominent in pts with bone sarcomas.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5939 - Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer
Presenter: Olga Simonova
Session: Poster Display session 1
Resources:
Abstract
2703 - Uveal melanoma cell lines depend on multiple signaling pathways for survival
Presenter: John Park
Session: Poster Display session 1
Resources:
Abstract
4849 - XAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition.
Presenter: Sungchan Jang
Session: Poster Display session 1
Resources:
Abstract
4801 - XAF1 assembles a destructive complex to induce BRCA1-mediated apoptosis via suppressing ERa and switching estrogen function
Presenter: Seung-hun Jang
Session: Poster Display session 1
Resources:
Abstract
3416 - Cancer associated fibroblasts promote cancer progression via Wnt2 secretion in colorectal cancer
Presenter: Hideaki Karasawa
Session: Poster Display session 1
Resources:
Abstract
4273 - Paired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer
Presenter: Jung-jyh Hung
Session: Poster Display session 1
Resources:
Abstract
4241 - LncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin
Presenter: Xin Guo
Session: Poster Display session 1
Resources:
Abstract
5388 - GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
5208 - Characterisation of growth hormone signal transduction in primary melanoma cell lines
Presenter: Karla Sousa
Session: Poster Display session 1
Resources:
Abstract
3156 - LAPTM5 protein can regulate TGF-β mediated MAPK and Smad signaling pathways in ovarian cancer cell
Presenter: Yan Gao
Session: Poster Display session 1
Resources:
Abstract